An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Arcus Biosciences, Inc. (RCUS) to present new data from phase 2 studies of novel immuno-oncology combinations at the 2024 ASCO Annual Meeting. The company will showcase updated data from EDGE-Gastric and ARC-9 studies, as well as a trial in progress for VELOCITY-Lung Substudy-03. The presentations highlight potential therapies for upper gastrointestinal, colorectal, and lung cancers, emphasizing the promising outcomes of investigational medicines across multiple cancer types.
Arcus Biosciences, Inc. (RCUS) presenterà nuovi dati provenienti da studi di fase 2 su combinazioni innovative di immuno-oncologia al Meeting Annuale ASCO del 2024. La compagnia esporrà dati aggiornati dagli studi EDGE-Gastric e ARC-9, così come uno studio in corso per il sottostudio VELOCITY-Lung Substudy-03. Le presentazioni metteranno in luce potenziali terapie per i tumori gastrointestinali superiori, colorettali e polmonari, sottolineando gli esiti promettenti dei medicinali sperimentali per diversi tipi di cancro.
Arcus Biosciences, Inc. (RCUS) presentará nuevos datos de estudios de fase 2 sobre combinaciones innovadoras de inmuno-oncología en la Reunión Anual de ASCO de 2024. La compañía mostrará datos actualizados de los estudios EDGE-Gastric y ARC-9, así como un ensayo en progreso para el subestudio VELOCITY-Lung Substudy-03. Las presentaciones destacarán posibles terapias para cánceres del tracto gastrointestinal superior, colorrectal y de pulmón, enfatizando los resultados prometedores de medicamentos en investigación para múltiples tipos de cáncer.
Arcus Biosciences, Inc. (RCUS)는 2024년 ASCO 연례 회의에서 새로운 면역-종양 복합치료에 관한 2상 연구 결과를 발표할 예정입니다. 회사는 EDGE-Gastric 및 ARC-9 연구의 최신 데이터와 VELOCITY-Lung Substudy-03의 진행 중인 시험을 선보일 것입니다. 이 발표들은 상부 위장관, 대장직장 및 폐암을 위한 잠재적인 치료법을 강조하며, 다양한 암 유형에 걸친 조사 중인 의약품의 유망한 결과를 강조할 것입니다.
Arcus Biosciences, Inc. (RCUS) présentera de nouvelles données issues d'études de phase 2 sur des combinaisons novatrices en immuno-oncologie lors de la Réunion Annuelle de l'ASCO 2024. La société exposera les données mises à jour des études EDGE-Gastric et ARC-9, ainsi qu'un essai en cours pour la sous-étude VELOCITY-Lung Substudy-03. Les présentations mettront en avant des thérapies potentielles pour les cancers du haut appareil gastro-intestinal, colorectal et pulmonaire, soulignant les résultats prometteurs des médicaments en investigation pour plusieurs types de cancer.
Arcus Biosciences, Inc. (RCUS) wird neue Daten aus Phase-2-Studien zu neuen immuno-onkologischen Kombinationstherapien auf der Jahrestagung der ASCO 2024 präsentieren. Das Unternehmen wird aktualisierte Daten aus den EDGE-Gastric und ARC-9-Studien vorstellen, sowie eine laufende Studie für die VELOCITY-Lung Substudie-03. Die Präsentationen werden potenzielle Therapien für obere gastrointestinale, kolorektale und Lungenkrebs hervorheben und die vielversprechenden Ergebnisse von Untersuchungsmedikamenten bei verschiedenen Krebsarten betonen.
Positive
Strong support for Arcus Biosciences' investigational medicines across various cancer types
Presentation of updated data from EDGE-Gastric and ARC-9 studies at the 2024 ASCO Annual Meeting
Focus on novel immuno-oncology mechanisms and combinations in gastrointestinal cancers
Highlighted outcomes for therapies in upper gastrointestinal, colorectal, and lung cancers
Negative
None.
Updated data from EDGE-Gastric evaluating domvanalimab plus zimberelimab and chemotherapy in upper gastrointestinal (GI) cancers will be presented in a special ASCO plenary series rapid abstract update session by Yelena Y. Janjigian, M.D., Chief Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center, and Lead Investigator for the EDGE-Gastric study
Data from ARC-9 evaluating an etrumadenant plus zimberelimab-based treatment combination in third-line metastatic colorectal cancer will be presented in an oral presentation by Zev A. Wainberg, M.D., MSc, Co-Director UCLA Gastrointestinal Oncology Program, and Lead Investigator for the ARC-9 study
Trial in Progress (TIP) poster for VELOCITY-Lung Substudy-03, a Phase 2 study of perioperative domvanalimab plus zimberelimab and chemotherapy in patients with resectable Stage II-III non-small cell lung cancer
HAYWARD, Calif.--(BUSINESS WIRE)--
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced three accepted abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 – June 4, 2024. The selected abstracts presented in partnership with Gilead Sciences provide strong support for the companies’ portfolio of investigational medicines across multiple types of cancer, including lung, upper GI and colorectal cancer.
“We will have two oral presentations for Phase 2 studies that highlight the potential for novel immuno-oncology mechanisms and combinations in gastrointestinal cancers,” said Terry Rosen, Ph.D., chief executive officer of Arcus. “The EDGE-Gastric presentation will include the median progression-free survival (PFS) data for our Fc-silent anti-TIGIT antibody in combination with zimberelimab and chemotherapy in upper GI cancers, the same setting as our STAR-221 Phase 3 study. The ARC-9 presentation will include randomized PFS and overall survival data for an etrumadenant (our adenosine receptor antagonist)-based combination therapy versus regorafenib, an approved standard of care in third-line colorectal cancer.”
Three Accepted Abstracts Will Be Presented
Study
Title
Abstract Number
Session Type &
Title
Session Date
& Time
Domvanalimab (Fc-silent anti-TIGIT monoclonal antibody) plus Zimberelimab (anti-PD-1 antibody)
EDGE-Gastric
Updates on Abstract 433248: EDGE-Gastric Arm A1: Phase 2 study of domvanalimab, zimberelimab, and FOLFOX in first-line (1L) advanced gastroesophageal cancer.
433248
ASCO Plenary Series: Rapid Abstract Updates
6/01/2024,
12:30 PM –
1:30 PM CT
VELOCITY-Lung Substudy-03 TIP
VELOCITY-Lung substudy-03: A phase 2 study of neoadjuvant domvanalimab (dom)+zimberelimab (zim)+chemotherapy (chemo) or zim+chemo followed by adjuvant dom+zim or zim in patients with resectable stage II-III non-small cell lung cancer (NSCLC).
ARC-9: A Randomized Study to Evaluate Etrumadenant-Based Treatment Combinations in Previously Treated Metastatic Colorectal Cancer (mCRC)
3508
Gastrointestinal Cancer—Colorectal and Anal: Oral Abstract Session
6/2/2024,
8:00 AM –
11:00 AM CT
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor), HIF-2a, CD39 and AXL. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.
Domvanalimab, zimberelimab and etrumadenant are investigational molecules. Neither Gilead nor Arcus has received approval from any regulatory authority for any use of these molecules, and their safety and efficacy for the treatment of gastrointestinal and lung cancers have not been established.
The Arcus name and logo are trademarks of Arcus Biosciences, Inc. All other trademarks belong to their respective owners.
arcus biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the san francisco bay area, in the heart of the world’s largest biotechnology research hub. unlike many other organizations, we view the drug discovery process as one that requires equal parts of technology and art, science and elegance, not as a commodity that can be outsourced. for this reason, we have assembled and are continuing to build an internal team of uniquely qualified individuals with extraordinary knowledge, skills and drive. arcus is rapidly establishing a portfolio of novel therapeutics encompassing both small molecules and biologics that target various facets of the immune system implicated in pathology or modulation of the cellular processes of cancer. these new drugs will then be
